They found that although the majority of nevi bear mutations that activate the RAS/MAPK axis, the vast majority of benign lesions are negative (or modestly positive) for mTORC1 activation, whereas more than 70% of melanomas display strong mTOR-dependent S6 phosphorylation [281]. This evidence concerns the gene MTOR and melanoma.